Sigal Charles Elliott — SEC insider filings

SEC reporting owner CIK 1661908. 22 insider filings on record with FilingPulse; latest filed 2026-11-12.

Transaction summary — filings shown

Covers all 22 filings on record, filed 2020-10-13 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Vir Biotechnology, Inc. (VIR)Director104 legs · 10,000 sh · $246,340—13
ALNYLAM PHARMACEUTICALS, INC. (ALNY)Director61 leg · 1,600 sh · $243,600—7
Surface Oncology, Inc. (SURF)Director3——4
Adaptimmune Therapeutics PLC (ADAP)Director3——3

Insider filings — Sigal Charles Elliott

FiledFormIssuerReported transactionsSource
2026-11-124ALNYLAM PHARMACEUTICALS, INC. (ALNY)Purchase (P): 1,600 @ $152.25EDGAR
2026-05-284Vir Biotechnology, Inc. (VIR)Grant/award (A): 8,000 @ $0 · Grant/award (A): 16,000 (derivative) @ $0EDGAR
2026-05-224ALNYLAM PHARMACEUTICALS, INC. (ALNY)Grant/award (A): 671 @ $0 · Grant/award (A): 1,441 (derivative) @ $0EDGAR
2025-06-024Vir Biotechnology, Inc. (VIR)Grant/award (A): 8,000 @ $0 · Grant/award (A): 16,000 (derivative) @ $0EDGAR
2025-05-124ALNYLAM PHARMACEUTICALS, INC. (ALNY)Grant/award (A): 775 @ $0 · Grant/award (A): 1,558 (derivative) @ $0EDGAR
2024-06-034Vir Biotechnology, Inc. (VIR)Grant/award (A): 8,000 @ $0 · Grant/award (A): 16,000 (derivative) @ $0EDGAR
2024-05-204ALNYLAM PHARMACEUTICALS, INC. (ALNY)Grant/award (A): 5,228 (derivative) @ $0EDGAR
2023-09-084Surface Oncology, Inc. (SURF)Disposition to issuer (D): 45,453 · Disposition to issuer (D): 113,636 (derivative) @ $0EDGAR
2023-07-034Adaptimmune Therapeutics PLC (ADAP)Grant/award (A): 933,317 (derivative) @ $0EDGAR
2023-05-244Vir Biotechnology, Inc. (VIR)Grant/award (A): 6,027 @ $0 · Grant/award (A): 12,054 (derivative) @ $0EDGAR
2023-05-194ALNYLAM PHARMACEUTICALS, INC. (ALNY)Grant/award (A): 3,454 (derivative) @ $0EDGAR
2023-03-024Vir Biotechnology, Inc. (VIR)Purchase (P): 2,500 @ $22.73EDGAR
2023-01-094Vir Biotechnology, Inc. (VIR)Purchase (P): 2,500 @ $24.96EDGAR
2023-01-054Vir Biotechnology, Inc. (VIR)Purchase (P): 2,500 @ $25.60 · Purchase (P): 2,500 @ $25.25EDGAR
2022-08-244ALNYLAM PHARMACEUTICALS, INC. (ALNY)Grant/award (A): 4,456 (derivative) @ $0EDGAR
2022-07-014Adaptimmune Therapeutics PLC (ADAP)Grant/award (A): 737,050 (derivative) @ $0EDGAR
2022-06-104Surface Oncology, Inc. (SURF)Grant/award (A): 24,000 (derivative) @ $0EDGAR
2022-05-254Vir Biotechnology, Inc. (VIR)Grant/award (A): 6,405 @ $0 · Grant/award (A): 12,810 (derivative) @ $0EDGAR
2021-07-024Adaptimmune Therapeutics PLC (ADAP)Grant/award (A): 474,385 (derivative) @ $0EDGAR
2021-06-104Surface Oncology, Inc. (SURF)Grant/award (A): 17,700 (derivative) @ $0EDGAR
2021-05-254Vir Biotechnology, Inc. (VIR)Grant/award (A): 3,374 @ $0 · Grant/award (A): 6,748 (derivative) @ $0EDGAR
2020-10-134/AVir Biotechnology, Inc. (VIR)Grant/award (A): 28,394 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-10-09 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1661908 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs